Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases: 2019-2024

Historic Current Leases for Autolus Therapeutics (AUTL) over the last 6 years, with Dec 2024 value amounting to $3.0 million.

  • Autolus Therapeutics' Current Leases rose 35.31% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 35.31%. This contributed to the annual value of $3.0 million for FY2024, which is 40.67% down from last year.
  • Per Autolus Therapeutics' latest filing, its Current Leases stood at $3.0 million for FY2024, which was down 40.67% from $5.1 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Current Leases peaked at $5.1 million during FY2023, and registered a low of $3.0 million during FY2024.
  • Its 3-year average for Current Leases is $4.4 million, with a median of $5.0 million in 2022.
  • Per our database at Business Quant, Autolus Therapeutics' Current Leases spiked by 42.97% in 2020 and then slumped by 40.67% in 2024.
  • Autolus Therapeutics' Current Leases (Yearly) stood at $3.6 million in 2020, then rose by 24.04% to $4.5 million in 2021, then increased by 13.14% to $5.0 million in 2022, then climbed by 0.30% to $5.1 million in 2023, then slumped by 40.67% to $3.0 million in 2024.